Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Wrist access may ease liver cancer treatment

NCT ID NCT07160374

Disease control Sponsor: Asan Medical Center Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 26, 2026 · Last updated Jun 26, 2026

Summary

This study tested a new way to deliver chemo directly to liver tumors using a wrist artery instead of the groin. Thirty-eight patients with liver cancer took part. The goal was to see if the wrist approach is safe, feasible, and effective, with fewer complications and faster recovery.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
HepaSphere drug-eluting microspheres
What this could lead to
If successful, this approach could make TACE safer and more comfortable for liver cancer patients, with faster recovery.
What could go wrong
This is a small, single-center study with only 38 participants. Results may not apply to all patients, and the procedure still carries risks like bleeding or infection.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

38 people

The number who actually took part.

Started

Aug 2018

Finished

Aug 2025

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

Patients with hepatocellular carcinoma treated at Asan Medical Center, Seoul, Korea.

Ages

19 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: \- Inclusion Criteria: * Age between 19 and 80 years * Diagnosed with hepatocellular carcinoma (HCC) * Child-Pugh class A * ECOG performance status 0 or 1 * Tumor size between 3 and 10 cm, with 1 to 7 nodules * Ability to provide written informed consent Exclusion Criteria: * Child-Pugh class B or C * Presence of other malignancies * CKD stage 4 or 5 (eGFR \< 30 mL/min/1.73m²) * Known allergy or contraindication to contrast media * Pregnancy or breastfeeding

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Hepatocellular carcinoma are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

hepatocellular carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Hepatocellular carcinoma

Contacts and locations

Locations

  • Asan Medical Center

    Seoul, Songpa-gu, 05505, South Korea

More trials for these conditions

Other studies related to the condition(s) this trial covers.